News | June 14, 2026
India clears major milestone in cervical cancer fight with validation of first indigenous HPV DNA test
Cervical cancer remains one of the leading causes of cancer deaths among women in India
Cervical cancer remains one of the leading causes of cancer deaths among women in India
Molbio Diagnostics' Truenat HPV-HR Plus becomes the world's first formally validated reduced-valency HPV test, meeting WHO-IARC standards
Hologic has been at the forefront of cervical cancer screening for decades
cSCC is one of the most common cancers in the U.S. and globally
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
The Indian government will float a global tender in April 2023 to procure HPV vaccines.
‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Supply increase to help meet growing global demand
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
